Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro

Hideji Fujii, Teruyo Takada, Kyuichi Nemoto, Fuminori Abe, Akio Fujii, James E. Talmadge, Tomio Takeuchi

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Deoxyspergualin (DSG) has demonstrated potent immunosuppressive activities in vivo. However, because of its lability in culture medium, the mechanism of activity has not yet been identified in vitro. In this study, a more stable analogue, deoxymethylspergualin (MeDSG), was used to investigate the in vitro immunosuppressive activity of DSG. MeDSG suppressed both human mixed lymphocyte reaction (MLR) and cytotoxi T-lymphocyte (CTL) activity at doses greater than 0.1 μg/ml in vitro. In kinetics studies, MeDSG was found to suppress a MLR when added on day 3 of a 7 day MLR incubation but cyclosporin A (CYA) suppressed a MLR only when added during the initial stage of a MLR (i.e. on day 1). In studies of cell surface phenotype in the MLR, MeDSG treatment decreased the numbers of CD8+ lymphocytes but those of CD4+ lymphocytes were not affected. In addition, MeDSG had no significant effect on interleukin-2 (IL-2) receptor expression or IL-2 production. These results suggest that MeDSG suppresses the T-cells which are proliferating competent cells such as cytotoxic T-cells (CD8+), but has a different mode of immunosuppressive action compared with CYA.

Original languageEnglish (US)
Pages (from-to)731-737
Number of pages7
JournalInternational Journal of Immunopharmacology
Volume14
Issue number4
DOIs
StatePublished - May 1992

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Fingerprint Dive into the research topics of 'Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro'. Together they form a unique fingerprint.

  • Cite this